Literature DB >> 21556022

Cancer: a roadmap for the land of small tumors.

Robert T Jensen.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21556022     DOI： 10.1038/nrendo.2011.73

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Promising advances in the treatment of malignant pancreatic endocrine tumors.

Authors:  Robert T Jensen; Gianfranco Delle Fave
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

Review 2.  Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.

Authors:  Dik J Kwekkeboom; Wouter W de Herder; Eric P Krenning
Journal:  Endocrinol Metab Clin North Am       Date:  2011-03       Impact factor: 4.741

3.  Karnofsky memorial lecture. An odyssey in the land of small tumors.

Authors:  C G Moertel
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

4.  Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.

Authors:  Matthew H Kulke; Lillian L Siu; Joel E Tepper; George Fisher; Deborah Jaffe; Daniel G Haller; Lee M Ellis; Jacqueline K Benedetti; Emily K Bergsland; Timothy J Hobday; Eric Van Cutsem; James Pingpank; Kjell Oberg; Steven J Cohen; Mitchell C Posner; James C Yao
Journal:  J Clin Oncol       Date:  2011-01-24       Impact factor: 44.544

5.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

6.  Everolimus for advanced pancreatic neuroendocrine tumors.

Authors:  James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

Review 7.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

8.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

Review 9.  Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.

Authors:  David C Metz; Robert T Jensen
Journal:  Gastroenterology       Date:  2008-08-12       Impact factor: 22.682

Review 10.  Gastroenteropancreatic neuroendocrine tumours.

Authors:  Irvin M Modlin; Kjell Oberg; Daniel C Chung; Robert T Jensen; Wouter W de Herder; Rajesh V Thakker; Martyn Caplin; Gianfranco Delle Fave; Greg A Kaltsas; Eric P Krenning; Steven F Moss; Ola Nilsson; Guido Rindi; Ramon Salazar; Philippe Ruszniewski; Anders Sundin
Journal:  Lancet Oncol       Date:  2008-01       Impact factor: 41.316
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.